十余家核聚变产业链企业在京路演，市场重点关注这些领域

Core Insights - The market is increasingly interested in exploring diverse routes in nuclear fusion technology beyond the mainstream Tokamak approach, with a focus on private startups showcasing their technologies and commercialization plans [1][2] Group 1: Investment and Market Trends - The recent nuclear fusion technology conversion event in Beijing attracted multiple investment institutions and 17 industry chain companies, highlighting the growing interest in private startups [1] - Investment in the global nuclear fusion sector has surged from $1.9 billion in 2021 to $9.7 billion currently, with the number of related companies increasing by 143% compared to 2023 [2] - Domestic investments are also on the rise, with significant funding rounds reported, including nearly 11.5 billion yuan for China Fusion and 500 million yuan for Nova Fusion [3] Group 2: Technological Developments - The diversification of technological routes is reshaping the nuclear fusion landscape, with new approaches like FRC showing cost advantages over traditional Tokamak systems [2] - The HHMAX-901 FRC device costs approximately 200 million yuan and can achieve electricity costs comparable to existing thermal power, with reusable key components for future iterations [2] - Medical applications of nuclear fusion technology are emerging, particularly in neutron therapy and isotope production, addressing market demands for targeted treatments [4] Group 3: Industry Opportunities - The nuclear fusion industry chain in China is developing clear investment opportunities, with significant funding directed towards core devices and supporting components [3] - The expansion of application scenarios, including medical fields, is opening new market possibilities, with a focus on boron isotope separation technology [3][4] - Investment firms are looking to support a variety of technological routes, including FRC and laser fusion, to foster innovative startups in the nuclear fusion sector [5]